Shares of Chemed Corporation (NYSE:CHE – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $555.50.
A number of research firms have recently commented on CHE. Jefferies Financial Group lowered shares of Chemed from a “buy” rating to a “hold” rating in a research note on Thursday, January 22nd. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Chemed in a research report on Wednesday, January 21st. Royal Bank Of Canada lowered their price objective on Chemed from $589.00 to $572.00 and set an “outperform” rating for the company in a research report on Monday, November 10th. Finally, Zacks Research raised Chemed from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 30th.
View Our Latest Stock Analysis on Chemed
Chemed Stock Performance
Chemed Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Monday, November 17th were issued a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Monday, November 17th. Chemed’s dividend payout ratio is presently 12.69%.
Insider Activity at Chemed
In other news, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction on Monday, November 24th. The shares were sold at an average price of $437.55, for a total value of $875,100.00. Following the completion of the sale, the chief executive officer owned 94,197 shares in the company, valued at $41,215,897.35. The trade was a 2.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 3.29% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Chemed
Large investors have recently bought and sold shares of the stock. Smartleaf Asset Management LLC boosted its position in shares of Chemed by 71.4% during the 3rd quarter. Smartleaf Asset Management LLC now owns 60 shares of the company’s stock worth $27,000 after purchasing an additional 25 shares in the last quarter. Creekmur Asset Management LLC bought a new stake in shares of Chemed during the second quarter valued at approximately $28,000. First Horizon Corp acquired a new position in shares of Chemed during the third quarter worth approximately $31,000. Pilgrim Partners Asia Pte Ltd bought a new position in shares of Chemed in the 3rd quarter worth $45,000. Finally, Parkside Financial Bank & Trust grew its position in Chemed by 86.3% in the 2nd quarter. Parkside Financial Bank & Trust now owns 95 shares of the company’s stock valued at $46,000 after purchasing an additional 44 shares during the period. 95.85% of the stock is currently owned by institutional investors and hedge funds.
About Chemed
Chemed Corporation is a diversified provider of essential home services and healthcare solutions in the United States. Headquartered in Cincinnati, Ohio, the company operates through two principal business segments—Roto-Rooter and Vitas Healthcare. Since its founding in 1974, Chemed has built a reputation for reliability and expertise, serving both residential and commercial customers across a broad range of markets.
The Roto-Rooter segment offers a comprehensive suite of plumbing, drain cleaning and water restoration services.
Featured Articles
- Five stocks we like better than Chemed
- The day the gold market broke
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Trump Planning to Use Public Law 63-43: Prepare Now
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.
